Hormonal
Skeletal muscle transcriptomic profiling, specifically focusing on a core set of 332 insulin-sensitive genes (CORE-IS) and non-coding RNAs, provides a robust molecular signature for metabolic disease that correlates with genetic loci identified by GWAS and responds to clinical interventions.
This research does not offer a direct lifestyle or supplement intervention. Instead, it highlights that current genetic testing (GWAS) is insufficient for predicting metabolic disease risk without functional data. It suggests that future diagnostics may rely on gene expression profiles (transcriptomics) from muscle tissue to accurately assess insulin sensitivity and metabolic health, potentially guiding personalized treatment strategies for type 2 diabetes and obesity.
we identified 332 fasting IS-related genes (CORE-IS). Over 200 had a proven role in the biochemistry of insulin and/or metabolism or were located at GWAS MD loci. Over 50% of the CORE-IS genes responded to clinical treatment; 16 quantitatively tracking changes in IS across four independent studies
Why this rating
Large sample size (n=1,012), multi-cohort meta-analysis, rigorous statistical filtering (FDR), and validation across multiple independent intervention studies.
Source
A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease
James A. Timmons et al. · Nucleic Acids Research · 2018
DOI 10.1093/nar/gky570
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →